CTOs on the Move

BGG Group

www.bggworld.com

 
Since 1995, BGG (Beijing Gingko Group) has been a global leader in the manufacture and sourcing of clinically-supported ingredients for the dietary supplement, cosmetics, and food and beverage industries. BGG has provided the highest quality, natural ingredients to clients world-wide. We start with the highest quality, wild-crafted, organic and non-GMO raw materials and produce natural health products and nutritional solutions that aid and enhance people`s well-being and quality of life. BGG specializes in organic fruit extracts, marine botanicals, natural vitamins, herbal extracts, natural sweeteners and flavor enhancers.
  • Number of Employees: 1K-5K
  • Annual Revenue: $10-50 Million
  • www.bggworld.com
  • 18301 Von Karman Avenue Suite 570
    Irvine, CA USA 92612
  • Phone: 949.748.7348

Executives

Name Title Contact Details

Similar Companies

SalioGen Therapeutics

SalioGen Therapeutics is advancing the Exact DNA Integration Technology (EDIT) platform, the only genome engineering technology that is mammal-derived, for use in potentially curative non-viral gene therapy.

Seismic Therapeutic

We are The Machine Learning Immunology Company. Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics drug discovery and development process. Using our IMPACT™ platform, we are fully integrating machine learning with the key elements of biologics drug discovery – structural biology, protein engineering and translational immunology – to create optimized therapies for patients. Seismic Therapeutic has an emerging pipeline of novel approaches to address adaptive immune system dysregulation to treat autoimmune diseases. The company is backed by a strong syndicate of life sciences investors and is located in the Boston biotechnology hub.

Cereset

#Cereset is a wellness company that helps their clients relax their #brain to manage stress and achieve restful #sleep. 🧠💤 Centers across the US & Europe.

Zealand Pharma

Changing lives with next generation peptide therapeutics

Theravance

Theravance, Inc. is focused on maximizing the potential value of the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R), with the intention of providing capital returns to stockholders. Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement with GSK, Theravance is eligible to receive the associated royalty revenues from RELVAR(R)/BREO(R) ELLIPTA(R) (fluticasone furoate/vilanterol, "FF/VI"), ANORO(R) ELLIPTA(R) (umeclidinium bromide/vilanterol, "UMEC/VI") and if approved and commercialized, VI monotherapy. Theravance is also entitled to a 15% economic interest in any future payments made by GSK under agreements entered into prior to the spin-off of Theravance Biopharma, and since assigned to Theravance Respiratory Company, LLC, relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy and in combination with other therapeutically active components, such as an inhaled corticosteroid, and any other product or combination of products that may be discovered and developed in the future under these agreements with GSK (other than RELVAR(R)/BREO(R) ELLIPTA(R), ANORO(R) ELLIPTA(R) and VI monotherapy).